Utility of real time breath analysis and physiologically based pharmacokinetic modeling to determine the percutaneous absorption of methyl chloroform in rats and humans.
Due to the large surface area of the skin, percutaneous absorption has the potential to contribute significantly to the total bioavailability of some compounds. Breath elimination data, acquired in real-time using a novel MS/MS system, was assessed using a PBPK model with a dermal compartment to determine the percutaneous absorption of methyl chloroform (MC) in rats and humans from exposures to MC in non-occluded soil or occluded water matrices. Rats were exposed to MC using a dermal exposure cell attached to a clipper-shaved area on their back. The soil exposure cell was covered with a charcoal patch to capture volatilized MC and prevent contamination of exhaled breath. This technique allowed the determination of MC dermal absorption kinetics under realistic, non-occluded conditions. Human exposures were conducted by immersing one hand in 0.1% MC in water, or 0.75% MC in soil. The dermal PBPK model was used to estimate skin permeability (Kp) based on the fit of the exhaled breath data. Rat skin K(p)s were estimated to be 0.25 and 0.15 cm/h for MC in water and soil matrices, respectively. In comparison, human permeability coefficients for water matrix exposures were 40-fold lower at 0.006 cm/h. Due to evaporation and differences in apparent Kp, nearly twice as much MC was absorbed from the occluded water (61.3%) compared to the non-occluded soil (32.5%) system in the rat. The PBPK model was used to simulate dermal exposures to MC-contaminated water and soil in children and adults using worst-case EPA default assumptions. The simulations indicate that neither children nor adults will absorb significant amounts of MC from non-occluded exposures, independent of the length of exposure. The results from these simulations reiterate the importance of conducting dermal exposures under realistic conditions.
Poet
T S
TS
Battelle, Pacific Northwest Division, Richland, Washington 99352, USA. torka.poet@pnl.gov
Thrall
K D
KD
Corley
R A
RA
Hui
X
X
Edwards
J A
JA
Weitz
K K
KK
Maibach
H I
HI
Wester
R C
RC
D000287:Administration, Topical; D000328:Adult; D000818:Animals; D001682:Biological Availability; D001823:Body Composition / Q000502:physiology; D001944:Breath Tests; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008954:Models, Biological; D051381:Rats; D011916:Rats, Inbred F344; D012869:Skin Absorption; D012997:Solvents; D014018:Tissue Distribution; D014240:Trichloroethanes / Q000008:administration & dosage / Q000493:pharmacokinetics*
D012997:Solvents; D014240:Trichloroethanes; C024566:1,1,1-trichloroethane